BeNeLuxBelgiumNetherlandsLuxembourg

Fluorescent tumours in the clinic

15.12.2011

Munich/Groningen/Penzberg – For ten years, the application of image-guided surgery with tumour-specific fluorescent dyes has been limited to animal studies, because no one could predict safety or bio­distribution of such targeted dyes in patients. Now for the first time, a Dutch-German team of researchers has found a way to convince regulatory authorities that their fluorochromes are safe and can be tested on human subjects. In November, the team got the go-ahead for a Phase I study in breast cancer patients with the fluorochrome IR dye 800 CW (LI-COR Bioscience) coupled to the antibody drug Avastin (Roche).
“Our advantage is that we already have a lot of clinical data about the safety and biodistribution of the cancer therapeutic Avastin, which binds to VEGF produced by cancer cells,” said Werner Scheuer from Pharma Research & Early Development at Roche (Penzberg), who developed the anti­body-flurochrome conjugates in cooperation with Vasilis Ntziachristos (TU Munich) and Go van Dam (Medical College Groningen). In the November issue of the Journal of Nuclear Medicine (52(11): 1778-1785), the authors provided evidence that their cancer imaging agent behaves in animals as Avastin does in humans. For proving safety in humans, they will use microdoses of the dye – 100 times lower than the lowest dose in which the cancer drug shows an effect. “We want to statistically prove that breast cancer patients benefit from image-guided surgery with targeted fluorochromes,” explains Ntziachristos. He has developed a camera system that can identify the tumour margins with seven times better resolution than a surgeon can with the naked eye. A pipeline of antibody-fluorochrome conjugates is already being tested in animals.

BeNeLux, Tech ReviewBelgiumNetherlandsLuxembourg

12.07.2007

Traditionally, nutritional science has focused largely on nutritional deficiencies and their impact on health and disease. Over the past few decades, research emphasis has gradually shifted to the relationship between...

BeNeLuxBelgiumNetherlandsLuxembourg

12.07.2007

Ghent – Researchers from VIB, Flanders Interuniversity Institute of Biotechnology have found a molecule which shields the skin from damages from UV-B rays and dehydration. They believe that overprotection of Caspase-14 could open...

BeNeLuxBelgiumNetherlandsLuxembourg

11.07.2007

Amsterdam – The Dutch ingredients firm DSM has announced plans to carve out its anti-infectives unit and initiate a partnering strategy with firms in low-cost areas such as India or China. DSM’s anti-infectives business supplies...

BeNeLuxBelgiumNetherlandsLuxembourg

11.07.2007

Leuven – The Belgian regenerative medicine specialist TiGenix has submitted a Marketing Authorisation Application (MAA) to the EMEA with the aim of gaining central approval for ChondroCelect, the company’s product candidate for...

BeNeLuxBelgiumNetherlandsLuxembourg

11.07.2007

Luxembourg – The coming year could be a turning point for research policy in Luxembourg. After years of restructuring following changes in European law and the foundation of Luxembourg University in summer 2003, the Ministry for...

BeNeLuxBelgiumNetherlandsLuxembourg

09.07.2007

Amsterdam – At the end of June, gene therapy specialist Amsterdam Molecular Therapies NV (AMT) raised a50 million in an IPO and private placement at Euronext. The price was at the top of the proposed a8 to a10 bookbuilding range,...

BeNeLuxBelgiumNetherlandsLuxembourg

09.07.2007

Leuven – The Belgian drug developer Thrombogenics has raised a23.9 million through a private placement of 2.2 million shares for the price of a10.80 per share. The offering was 1.5 times oversubscribed and represented about 10%...

BeNeLux, Tech ReviewBelgiumNetherlandsLuxembourg

17.05.2007

Amsterdam – Researchers from the gene therapy company Amsterdam Molecular Therapeutics BV have presented proof of principle data for its gene therapy approach against Acute Intermittent Porphyria, an orphan hereditary disease due...

BeNeLuxBelgiumNetherlandsLuxembourg

16.05.2007

Leiden – Crucell N.V. has entered its rabies monoclonal antibody in Phase I clinical study in India, four months after launching a similar study in the US. The human monoclonal antibody product for the post-exposure prophy­laxis...

BeNeLuxBelgiumNetherlandsLuxembourg

16.05.2007

Leuven – TiGenix, a Belgian biomedical company focused on innovative local treatments for damaged and osteoarthritic joints has gone public at Euronext. The company raised a40 million through the sale of 8 million shares at a5 in...

Displaying results 191 to 200 out of 304

< Previous 191-200 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-benelux/browse/19/article/fluorescent-tumours-in-the-clinic.html

Print Magazine

Product of the week

Products

Events

All Events

Partner-Events

Stock list

All quotes

TOP

  • 4SC0.94 EUR2.17%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • ACTELION108.70 CHF0.00%
  • ADDEX3.07 CHF0.00%

TOP

  • CYTOS0.28 CHF75.0%
  • EPIGENOMICS5.15 EUR45.9%
  • STRATEC BIOMEDICAL48.50 EUR21.7%

FLOP

  • BIOFRONTERA2.52 EUR-13.1%
  • CO.DON2.51 EUR-8.7%
  • ADDEX3.07 CHF-7.0%

TOP

  • SANTHERA91.30 CHF2585.3%
  • CO.DON2.51 EUR139.0%
  • BB BIOTECH181.25 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.8%
  • 4SC0.94 EUR-46.0%
  • MOLOGEN7.35 EUR-41.4%

No liability assumed, Date: 22.11.2014

Current issue

All issues